|
It is the objective of this review to introduce the reader to the current status of
organometallic chemistry, oriented towards the development of novel 99mTc-based imaging
agents. This type of inorganic chemistry has nowadays become part of so-called bioorganometallic
chemistry.
The article describes the current state of research and development of radiopharmaceutical
imaging agents based on organometallic moieties and complexes. Organometallics are,
in general, not considered to play an important role in inorganic medicinal chemistry. An
introductory section describes the requirements for practical application of a radiopharmaceutical
to underline in the second part that currently available compounds might well
be the basis for the development of completely new imaging agents. The introduction gives
also a short outline of basic organometallic technetium compounds as well as organometallic
aqua ions from other elements which are currently under investigation in the new
field of bioorganometallic chemistry.
Berlex International Project Management Oncology, Montville, NJ. Provides information on radiopharmaceutical contrast agents and their new developments used as therapeutic drugs. Topics covered include new organometallic technetium complexes and radiopharmaceuticals for positron emission tomography. |
|
|
|